🔎 Trials Near Me

Home › Chronic Myelomonocytic Leukemia › Ohio

Pag-aaral pangklinika para sa Chronic Myelomonocytic Leukemia sa Ohio

5 pag-aaral para sa Chronic Myelomonocytic Leukemia ang naghahanap ng mga kalahok sa mga site sa Ohio.

Mga Lungsod sa Ohio

Opisyal na teksto ng pag-aaral (English)

Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation

  • Ohio State University Comprehensive Cancer Center, Columbus
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 2, 2026 · NCT07249346

Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia

  • Ohio State University Comprehensive Cancer Center, Columbus
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 27, 2026 · NCT06523556

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

  • Ohio State University Comprehensive Cancer Center (OSUCCC) - The James Cancer Hospital and Solove Research Institute, Columbus
Nagre-recruitPhase 2/3
Edad 18 pataas · Lahat ng kasarian · Na-update Abr 30, 2026 · NCT04256317

Olutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell Transplant

  • Cleveland Clinic Cancer Center, Cleveland
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Mar 5, 2026 · NCT06543381

Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia

  • The Ohio State University Wexner Medical Center, Columbus
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 26, 2025 · NCT03850574

Mula sa ClinicalTrials.gov, na-kuha noong Okt 5, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.